These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 33549049)
1. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis. Yang K; Wu Y BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049 [TBL] [Abstract][Full Text] [Related]
2. Differential Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615 [TBL] [Abstract][Full Text] [Related]
3. Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma. Li XS; Nie KC; Zheng ZH; Zhou RS; Huang YS; Ye ZJ; He F; Tang Y BMC Cancer; 2021 Jan; 21(1):96. PubMed ID: 33485313 [TBL] [Abstract][Full Text] [Related]
4. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. Xu XL; Gong Y; Zhao DP Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913 [TBL] [Abstract][Full Text] [Related]
5. Zhang W; Li T; Hu B; Li H Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541 [TBL] [Abstract][Full Text] [Related]
6. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns. Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858 [TBL] [Abstract][Full Text] [Related]
7. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma. Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401 [TBL] [Abstract][Full Text] [Related]
8. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma. Yang Y; Wang M; Liu B J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601 [TBL] [Abstract][Full Text] [Related]
9. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients. Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283 [TBL] [Abstract][Full Text] [Related]
10. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer. Yu H; Pang Z; Li G; Gu T J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722 [TBL] [Abstract][Full Text] [Related]
11. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma. Hou G; Lu Z; Bi Y; Deng J; Yang X Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321 [TBL] [Abstract][Full Text] [Related]
12. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401 [TBL] [Abstract][Full Text] [Related]
13. System analysis of Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116 [TBL] [Abstract][Full Text] [Related]
14. Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma. Xu X; Zhang J; Yao T; Zhao X; Wu Q; Lu C; Guo X; Xie S; Qiu L; Bi R; Xue H Int Immunopharmacol; 2024 Sep; 139():112727. PubMed ID: 39067405 [TBL] [Abstract][Full Text] [Related]
15. Distinct Patterns of mRNA and lncRNA Expression Differences Between Lung Squamous Cell Carcinoma and Adenocarcinoma. Tian Y; Yu M; Sun L; Liu L; Wang J; Hui K; Nan Q; Nie X; Ren Y; Ren X J Comput Biol; 2020 Jul; 27(7):1067-1078. PubMed ID: 31750732 [TBL] [Abstract][Full Text] [Related]
16. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis. Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858 [TBL] [Abstract][Full Text] [Related]
18. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma. Zhao Y; Gao Y; Xu X; Zhou J; Wang H BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346 [TBL] [Abstract][Full Text] [Related]
19. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates. Meng F; Zhang L; Ren Y; Ma Q J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039 [TBL] [Abstract][Full Text] [Related]
20. The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases. Liang Y; Lei Y; Du M; Liang M; Liu Z; Li X; Gao Y J Cell Mol Med; 2021 Jul; 25(14):7039-7051. PubMed ID: 34117717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]